LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Australia and the Asia-Pacific region.

This exclusive, multi-year agreement solidifies the partnership, and enables both organizations to leverage complementary strengths to help get patients the medicines they need by meeting the growing regional demand of clinical trial support services for pharmaceutical, biotechnology, and clinical research organizations.

ACL Specialised Trials is one of the leading clinical trials laboratories in Australia, managing large biotech and pharmaceutical clinical trials from Phase 1 to Phase 4 studies. With a vast network of laboratories across Australia, ACL Specialised Trials has extensive experience in delivering end to end pathology solutions and a wide range of clinical trials central laboratory services for national, multi-site and single site clinical trial studies. 

"This long-term partnership will help global clients access Australian patients and bring key international trials to this part of the world – ultimately resulting in the advancement of leading-edge medical breakthroughs that can save lives and improve patient outcomes," stated ACL Group Executive CEO, Melinda McGrath. "It will strengthen our position as a key player in a growing $8 billion market and I am excited to showcase our depth of experience and talented team on the world stage. This is fantastic news for our communities, and we are proud to be partnering with LabConnect."

As the world's most agile central laboratory solutions partner, LabConnect will leverage ACL's extensive test menu with a comprehensive range of services to support the region including in-country lab kit building, biospecimen management, project and data management, and logistics support. Catherine Osborne, APAC General Manager, leads LabConnect's growing operations and business in the region.

As LabConnect's primary laboratory services provider for Australia and the broader APAC region, ACL Specialised Trials will support LabConnect with their dedicated, clinical trials laboratory and project team situated in Port Melbourne, Victoria, serving as the operational hub for the region. 

Wes Wheeler, LabConnect CEO, added, "Our clients increasingly include Asian Pacific investigative sites in their clinical development plans and our partnership with ACL Specialised Trials provides us with a platform from which we can deliver our comprehensive suite of industry-leading central laboratory services across the region."